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Abbreviations: ABHD, alpha-beta hydrolase; ACU, N-adamantyl-N’- 
cyclohexyl urea; AEPU, 1-((3S,5S,7S)-adamantan-1-yl)-3- 
(5-(2-(2-ethoxyethoxy)ethoxy)pentyl)urea; AUDA, 12-(3-adamantan-1-yl-
ureido)-dodecanoic acid; AUOA, 8-(3-((3S,5S,7S)-adamantan-1-
yl)ureido)octanoic acid; c-AUCB, 4-(((1S,4S)-4-(3-((3S,5S,7S)-adamantan-1-
yl)ureido)cyclohexyl)oxy)benzoic acid; CDU, 1-cyclohexyl-3-dodecylurea; 
EETs, epoxyeicosatrienoic acids; EH, epoxide hydrolase; peg1/MEST, 
paternally expressed gene 1/mesoderm specific transcript; t-AUCB, 4-
(((1R,4R)-4-(3-((3S,5S,7S)-adamantan-1-yl)ureido)cyclohexyl)oxy)benzoic 
acid; TPAU, 1-(1-acetylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea; t-
TAUCB, 4-(((1R,4R)-4-(3-
(4(trifluoromethoxy)phenyl)ureido)cyclohexyl)oxy)benzoic acid. 
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Abstract 
Epoxide hydrolases are a small superfamily of enzymes important for the 
detoxification of chemically reactive xenobiotic epoxides and for the 
processing of endogenous epoxides that act as signaling molecules. Here, we 
report the identification of two human epoxide hydrolases, EH3 and EH4. 
They share 45% sequence identity, thus representing a new family of 
mammalian epoxide hydrolases. Quantitative RT-PCR from mouse tissue 
indicates strongest EH3 expression in lung, skin, and upper gastrointestinal 
tract. The recombinant enzyme shows a high turnover number with 8,9-, 
11,12- and 14,15-epoxyeicosatrienoic acid (EET), as well as 9,10-
epoxyoctadec-11-enoic acid (leukotoxin). It is inhibited by a sub-class of N,N’-
disubstituted urea derivatives, including 12-(3-adamantan-1-yl-ureido)-
dodecanoic acid, 1-cyclohexyl-3-dodecylurea, and 1-(1-acetylpiperidin-4-yl)-3-
(4-(trifluoromethoxy)phenyl)urea, compounds so far believed to be selective 
inhibitors of mammalian soluble epoxide hydrolase (sEH). Its sensitivity to this 
subset of sEH inhibitors may have implications on the pharmacologic profile of 
these compounds. This is particularly relevant because sEH is a potential 
drug target and clinical trials are under way exploring the value of sEH 
inhibitors in the treatment of hypertension and diabetes type II. 
 
 
 
 
 
 
 
Keywords: epoxyeicosatrienoic acid, blood pressure, pain, diabetes type II 
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Introduction 
Epoxide hydrolases (EH) are enzymes that hydrolyze oxirane (epoxide) 
derivatives to the corresponding diols. They serve a plethora of vital functions, 
including detoxication of chemically reactive epoxides (1), formation of 
defense barriers by plants against herbivores (2), as well as the regulation of a 
large variety of physiological functions (3). The latter capability is due to the 
fact that a growing number of lipid-derived epoxides has been identified as 
signaling molecules in higher organisms. This is best documented for the 
arachidonic acid-derived epoxides, in particular the epoxyeicosatrienoic acid 
(EET) regioisomers, that have been shown to be involved in the regulation of 
e.g. blood pressure (4,5), pain perception (6,7), angiogenesis (8) and 
inflammation (9). Thus, pharmacologic intervention in the pathways controlling 
their biologic activity is an appealing target for drug development (10,11). 
The vast majority of EHs belong to the structural family of α/β hydrolase fold 
enzymes and share the same three-dimensional structure and enzymatic 
mechanism (12), with few exceptions (13-15). Two mammalian α/β hydrolase 
fold EHs have been described and studied in detail. The microsomal epoxide 
hydrolase (mEH) is the major player in the defense against reactive, 
xenobiotic-derived epoxides (16). Recent results suggest that it also plays a 
role in signaling molecule processing (17). The sister enzyme soluble epoxide 
hydrolase (sEH) (18) serves a prominent function in the processing of 
important signaling molecules (19,20), in particular EETs. In addition, it 
complements the detoxification function of mEH by inactivation of reactive 
trans-disubstituted epoxides (21), that escape the otherwise very broad mEH 
substrate spectrum. 
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Like all α/β hydrolase fold enzymes, EHs hydrolyze their substrate via 
intermediate formation of an enzyme-substrate ester (22,23). Two structural 
features in the active site allow to discriminate EHs from the large pool of 
other α/β hydrolase fold enzymes: i) EHs possess an aspartic acid residue as 
the catalytic nucleophile to form said ester intermediate, and ii) they use two 
tyrosines in their lid domain to recognize and activate the substrate (for details 
on the enzymatic mechanism see Supporting information S1). 
Based on such structural characteristics, we have identified three potential 
new mammalian EHs, and describe here the biochemical properties of one of 
these, namely EH3, in detail. This novel human EH, together with its relative 
EH4, forms a new family of mammalian EHs and displays a high turnover 
number with fatty acid-derived epoxides, indicating a role in the regulation of 
important physiological processes. 
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Results 
Sequence similarity search reveals three new human candidate epoxide 
hydrolases  
Previous sequence comparisons of epoxide hydrolase-related α/β hydrolase 
fold enzymes (22,24) revealed a highly conserved 16 amino acid sequence 
motif RVIAPDLRGYGDSDKP that was used as the bait in database searches 
for new epoxide hydrolase candidates. This resulted in the identification of 3 
new human proteins, designated ABHD7, ABHD9 and peg1/MEST. Their 
amino acid sequences are highly conserved among mammalian species. 
Further inspection of these sequences proved the presence of all signatures 
necessary for and compatible with an epoxide hydrolase function (detailed in 
Supporting Information SI2). Sequence alignment of these proteins with other 
well characterized EHs revealed that ABHD7 and ABHD9 are most similar to 
a recently described set of soluble epoxide hydrolases from Caenorhabditis 
elegans (25) and represent a new family of mammalian epoxide hydrolases, 
due to a shared sequence identity of 45%. A phylogenetic tree indicating this 
relationship is shown in Fig. 1. Based on the results reported in the following 
we have proposed to rename the ABHD9 and ABHD7 proteins to EH3 and 
EH4 and the corresponding genes to EPHX3 and EPHX4, respectively, which 
was approved by the human genome nomenclature committee, and we use 
these designations throughout (for the rational behind this nomenclature see 
Supporting Information SI3).  
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EH3 is a functional epoxide hydrolase 
We concentrated on the physicochemical and functional characterization of 
EH3 (ABHD9). The human gene has the chromosomal localization 19p13.12 
and codes for a 1.8 kb mRNA composed of 7 exons. The respective mRNA 
codes for a 360 aa protein with a predicted molecular weight and isoelectric 
point of 40’909 Da and pI 7.7, respectively. Residues 22 to 44 are exclusively 
hydrophobic in nature and are predicted to represent a membrane insertion 
signal. They are followed by a stretch of arginine residues that potentially acts 
as a stop transfer signal, suggesting a cytoplasmic orientation of the protein, 
similar to that reported for mEH (26).  
In order to investigate whether EH3 has the predicted catalytic function we 
recombinantly expressed the protein in E. coli. We failed to obtain detectable 
amounts when trying to express the complete protein. Instead, an N-terminally 
truncated version of EH3 carrying an N-terminal His-tag was found in 
appreciable amounts. The recombinant protein was obtained as inclusion 
bodies, and was therefore not useful for the analysis of enzymatic properties. 
We used it for rabbit immunization after purification and obtained an 
antiserum that was suitable for the detection of the protein by immunoblotting.  
Likewise, an attempt to obtain an enzymatically active EH3 via recombinant 
expression in yeast failed. 
The recombinant full length enzyme was eventually obtained by baculovirus-
mediated expression in insect cells. The yield of EH3 protein was low, 
routinely amounting to around 0.1 % of the total cellular protein, as proven by 
immunoblot analysis. In line with our prediction, the recombinant protein was 
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membrane-bound as demonstrated by the enrichment in the 100,000 x g 
pellet of the insect cell homogenate after differential centrifugation (Fig. 2). 
The insect cell homogenate was used to assess the catalytic capabilities of 
the recombinant enzyme. Neither styrene 7,8-oxide, a generic substrate that 
is hydrolyzed by most EHs (27), nor cholesterol 5,6-epoxide, a substrate for a 
membrane-bound human EH of which the identification has been reported 
during the preparation of the present manuscript (28), was converted to the 
corresponding diol by EH3. In contrast, we did detect a high turnover of 9,10-
epoxystearic acid with the recombinant cell lysate, an enzymatic activity that 
was essentially absent from mock-infected insect cell lysates.  
Being now capable of assessing the functional integrity of the enzyme, we 
tried to solubilize it from the membrane in order to attempt its purification. 
However, multiple trials with different types of detergents and a variety of 
different experimental conditions did not lead to the release of detectable 
amount of catalytic activity into the 100,000 x g supernatant. Therefore, we 
are, at present, not able to obtain the enzyme in a purified, catalytically active 
form. 
 
D173, Y220, Y281, D307 and H337 are the residues involved in EH3-
mediated catalysis     
Sequence comparisons (see Supplementary Information, Fig. SI2) suggested 
D173 as the catalytic nucleophile and H337-D307 as the charge relay system 
of the EH3 catalytic triad. Y281 and Y220 were the predicted candidates for 
the catalytic tyrosines in the lid domain of the enzyme. Y280 was, in addition, 
considered as a possible alternative because of its proximity to the 
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neighbouring Y281. In line with this, the respective mutants D173A, Y220F, 
Y281F, D307A, D307N, H337Q and H337A expressed in insect cells lacked 
any detectable hydrolytic activity with 9,10-epoxystearic acid (Fig. 3A), 
substantiating the importance of the five modified residues in substrate 
turnover (Fig. 3B). In contrast, the mutant Y280F displayed significant 
enzymatic activity, supporting that Y281 is the catalytic tyrosine and showing 
the lack of substantial effect of a single amino acid exchange when the 
respective residue is not directly involved in catalysis. In apparent 
contradiction to our working hypothesis, the mutant D173N showed a 
substrate turnover similar to that of the Y280F mutant. However, this is well 
compatible with the expected role of D173 as the catalytic nucleophile 
because self-activation by autocatalytic hydrolysis from the mutant asparagine 
to the wild type aspartic acid side chain has been reported for the equivalent 
mutants of other EHs (29,30). 
 
EH3 is highest expressed in mouse skin, lung and upper gastrointestinal tract 
To assess the expression pattern of the EH3, we isolated mRNA from a 
representative set of mouse organs and analyzed these by quantitative RT-
PCR (Fig. 4). The strongest signals for EH3 expression were obtained with 
RNA from skin, lung, tongue, esophagus and stomach. Intermediate 
expression was found in pancreas and eye, followed by visceral fat, lymph 
nodes, spleen, aortic arch (used for normalization) and heart. Low signals 
were obtained with RNA from kidney, testis, ovary intestine, brain and liver. 
The lowest, yet still detectable, expression was found in skeletal muscle. 
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Epoxyeicosatrienoic acids and leukotoxin are endogenous substrates of EH3 
The turnover of 9,10-epoxystearic acid raised the question whether other fatty 
acid-derived compounds can be hydrolyzed by EH3. We therefore looked at 
the turnover of EETs and leukotoxin as physiologically relevant substrate 
candidates. Indeed, EH3 efficiently hydrolyzed all these compounds. Fig. 5 
shows the respective kinetic analysis. The derived kinetic constants are given 
in Tab. 1, in comparison with data obtained with recombinant purified human 
sEH and mEH under the same conditions. All analyzed substrates were 
turned over by EH3 with high Vmax, yet also comparatively high Km, resulting in 
catalytic efficacies that are in the range of those obtained with sEH and mEH. 
The highest catalytic efficacy was observed with leukotoxin. Turnover of 5,6-
EET could not be quantified because the insect cell preparation displayed a 
significant background activity with this substrate.  
 
EH3 is inhibited by urea derivatives regarded as specific for sEH 
In view of the fact that EET turnover by EH is evolving as a promising target 
for therapeutic intervention (11), and in particular inhibitors of sEH are 
presently developed as potentially marketable drugs (10), we were interested 
in a possible interference of such drugs with the EH3-mediated turnover of 
signalling molecules. We tested a subset of representative EH inhibitors for 
their inhibitory potency on EH3 catalysis at relevant concentrations (Tab. 2). 
The potent inhibitors specific for mEH (elaidamide) and sEH (ACU) were 
essentially not affecting EH3 activity. Likewise, a new generation of sEH 
inhibitors with bulky structure, represented by 4-(((1R,4R)-4-(3-(4-
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(trifluoromethoxy)phenyl)ureido)cyclohexyl)oxy)benzoic acid (t-TAUCB), 4-
(((1S,4S)-4-(3-((3S,5S,7S)-adamantan-1-yl)ureido)cyclohexyl)oxy)benzoic 
acid (c-AUCB) and 4-(((1R,4R)-4-(3-((3S,5S,7S)-adamantan-1-yl) 
ureido)cyclohexyl)oxy)benzoic acid (t-AUCB), did not show any effect. 
However, a group of inhibitors hitherto believed to be specifically targeting 
sEH activity reduced EH3 hydrolysis of 8,9-EET significantly at a 
concentration of 1 µM. The most potent of these were 1-(1-acetylpiperidin-4-
yl)-3-(4-(trifluoromethoxy)phenyl)urea (TPAU), 1-cyclohexyl-3-dodecylurea 
(CDU) and 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), popular 
sEH inhibitors widely used for in vivo animal studies. We studied their 
inhibitory profile for EH3 in more detail and determined their IC50 (that is 
expected to equal Ki under the employed experimental conditions) to around 
100 nM (Fig. 6), thus well in the range to have the enzyme affected under the 
experimental conditions usually employed for in vivo sEH inhibition (31). 
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Discussion 
EH3 is a hitherto undiscovered mammalian epoxide hydrolase displaying a 
high turnover with fatty acid-derived epoxides, in particular EETs and 
leukotoxin, while being essentially inactive towards the generic EH substrate 
styrene oxide. This substrate selectivity suggests that the enzyme is 
implicated in processing of signaling molecules rather than detoxification of 
xenobiotic epoxides. It has the highest specific activity with EETs so far 
reported for an EH, and a catalytic efficacy being in the range of that of sEH, 
the major enzyme in EET turnover (20). Its expression pattern in the 
mammalian organism is quite different from that of the other well 
characterized EHs in that it is only poorly expressed in the liver but well 
expressed in skin, lung and upper gastrointestinal tract. Based on this 
observation, it is tempting to speculate on a potential role of EH3 in barrier 
formation, because the above tissues represent the major contact surfaces 
with the outside. Indeed, EH3 has been identified as a candidate disease 
gene for ichthyosis, based on comparative studies in human and mouse (32), 
which is compatible with such a function.  
Furthermore, we find EH3 to be the most efficient catalyst for the hydrolysis of 
leukotoxin. The resulting metabolite has been reported to be a strong 
mediator of acute lung failure (ARDS; (19)) which suggests that EH3 might 
contribute to leukotoxin toxicity, in particular since we find a particularly high 
EH3 expression in lung (see Fig. 4). 
Intriguingly, EH3 is sensitive to inhibition by N,N’-disubstituted urea 
derivatives, a class of compounds that has been developed as specific 
inhibitors for the mammalian sEH (33). In contrast to the latter enzyme, EH3 
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seems to be inhibited only by a subset of sEH inhibitors. Urea derivatives 
have been developed as EH inhibitors with the aim to pharmacologically 
interfere with the EET metabolism and have been proposed as potentially 
useful agents to treat high blood pressure (10), pain (7), and recently diabetes 
type II (34). Our present observation divides the urea derivatives into sEH 
selective inhibitors and mixed sEH and EH3 inhibitors. This has to be taken 
into account for the interpretation of in vivo data obtained with the different 
sets of compounds. Whether sEH-selective or the mixed-type blockade of 
EET hydrolysis is more favorable in the treatment of diseases remains to be 
established.  
The expression of the EPHX3 gene has been reported to be down regulated 
in a variety of tumors. Hypermethylation in the promoter region, associated 
with a reduced transcription rate, was observed in gastric cancer (35), 
prostate cancer (36) and melanoma (37). In view of the recently described 
potential of EETs to reactivate dormant tumors and foster metastasis (38), 
possibly related to the angiogenic properties of EETs (39), this suggests a 
potential role of EH3 in the prevention of malignancies.  
Finally, it is reasonable to speculate about why there are (at least) 3 separate 
EHs for the breakdown of bioactive fatty acid epoxides, namely EH3, sEH and 
mEH?  Apart from the simple answer that these differ somewhat in their 
substrate selectivity, there is an additional intriguing hypothesis to come up 
with: if we accept that the hydrolysis products, like the DHET and the 
leukotoxin diol, have their own biologic activity (40), sometimes distinct and 
possibly opposite to the effects elicited by the parent molecules, the local 
ratios in the concentration of epoxide to diol may dictate the signaling 
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outcome. Among the several factors that influence this ratio, the above 
enzymes particularly differ in two of them, subcellular localization and Km. 
The effect of the subcellular localization is obvious. The ER-resident EHs may 
have a significant kinetic advantage if they are expressed in the same cell as 
the epoxide-forming monooxygenase because they might directly hydrolyze 
the epoxide during their formation, yielding a high diol to epoxide ratio at low 
epoxide formation rates, as already discussed earlier for mEH (17). The major 
difference between mEH and EH3, the two ER resident EHs, is the enormous 
difference in their Km for fatty acid epoxides, while their catalytic efficacies are 
within the same range (see Tab. 1). The resulting consequences are best 
explained by looking at a kinetic diagram of the enzymes with a common 
substrate, 11,12-EET (Fig. 7). While both enzymes should afford a similar diol 
to epoxide ratio at low epoxide formation rates, this ratio would strongly 
decrease once the substrate concentration increases over the low mEH Km, 
while the ratio would stay constant with EH3, due to its extremely high Km 
that lies even beyond the highest locally expected substrate concentration. 
Thus, EH3 would be the most suitable EH under conditions where a high diol 
formation rate with only a small EET leakage is desired.  
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Materials and Methods 
 
Database screening for candidate epoxide hydrolases 
Screening of the “build protein” database on the NCBI Human Genome 
BLAST website was performed using the BLASTP algorithm with the amino 
acid sequence RVIAPDLRGYGDSDKP as the search motif. Obtained hits 
were inspected for the presence of other sequence motifs indicative of an EH 
function (detailed in Supporting Information SI2). 
 
Cloning and expression of EH3 
Human EH3 cDNA was amplified from the I.M.A.G.E. consortium clone 
2226429 (gene bank accession number AI570023). The full length cDNA was 
inserted into the pGEF II bacterial expression vector (29). A 5’-truncated cDNA 
lacking the coding region for the N-terminal 48 amino acid residues was 
cloned into the bacterial expression vector pRSET B (Invitrogen, Basel, CH) 
to obtain an anchorless, N-terminally His-tagged fusion protein. The resulting 
constructs were verified by sequencing and transformed into E. coli BL21AI 
for recombinant expression as described (41). For the expression in insect 
cells, the full length cDNA was inserted into the pFastBac plasmid (Invitrogen, 
Basel). Recombination with the baculovirus genome was achieved by 
transformation of the resulting pFastBac EH3 into E. coli DH10Bac. The 
resulting bacmid was purified, verified by PCR and sequencing, and used to 
transfect Sf9 insect cells to generate the intact recombinant baculovirus. 
Recombinant protein expression was accomplished by insect cell infection in 
suspension culture at a multiplicity of infection of 5. Five days post infection, 
cells were harvested. Lysates were obtained by a single pass through a 
Decker et al.   New human epoxide hydrolase for signaling molecules 15 
FrenchPress pressure cell (American Instrument Exchange, Haverhill, MA) at 
30’000 psi and stored at –80 °C until use. 
EH3 mutants were produced by mutating pFastBac EH3 via the 
Quikchange™ mutagenesis procedure (Stratagene, La Jolla, CA) and further 
processing as described above (for details see Supporting Information SI4). 
 
Subcellular fractionation and immunoblot analysis  
EH3 was purified under denaturing conditions by preparative coomassie blue-
SDS gel electrophoresis (42) from inclusion bodies obtained with the pRSET 
construct and used to raise antisera in rabbits as described previously (43). 
The resulting serum has a detection limit of 0.5 ng of recombinant human EH3 
per lane by Western blot analysis (44) at a dilution of 1:1000 using colorimetric 
detection (see below). To assess the subcellular distribution of EH3, insect 
cell lysates were subjected to differential centrifugation (10’000 x g for 20 min 
to pellet larger organelles, followed by 100’000 x g for 1 h to pellet membrane 
vesicles). Resulting fractions were analyzed by immunoblotting, using the 
EH3-specific rabbit antiserum (1:1000) and an alkaline phosphatase 
conjugated goat anti-rabbit secondary antibody (1:10’000; Sigma, St. Louis, 
MO), followed by colorimetric detection using NBT/X-Phosphate. As a positive 
control for the distribution of ER membrane vesicles in the above procedure, 
insect cells infected with a recombinant mEH-coding baculovirus were used. 
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Enzyme assays 
Enzymatic hydrolysis of 9,10-epoxystearic acid was assayed by a TLC-based 
procedure essentially as previously described (45), using a CycloneTM Storage 
Phosphor Scanner (PerkinElmer, Waltham, MA) for quantification of the 
radiometric signals. Hydrolysis of the different EET regioisomers was 
quantified in insect cell lysates by LC-MS/MS as described recently (17). 
Leukotoxin turnover was assayed under the same experimental conditions, 
using the mass transitions 295.2/171.1 and 313.2/201.1 for the quantification 
of leukotoxin and leukotoxin diol, respectively. Immunoquantification of EH3 in 
insect cell lysates is detailed in Supporting Information (SI5). For inhibition 
studies, EH3 lysates or purified human sEH were preincubated for 5min on 
ice with EH inhibitors at the indicated concentrations, prior to addition of the 
substrate.  
 
Expression analysis of EH3 in mouse tissues 
Tissues for mRNA analyses were taken from 12 week old C57BL/6 mice. 
Animals were sacrificed and organs were instantly removed by surgery and 
snap frozen in liquid nitrogen until further processing. Total RNA was isolated 
using RNeasy Mini Kit (Qiagen, Hilden, Germany). cDNA synthesis was 
performed with the High Capacity cDNA Archive Kit (Applied Biosystems). 
Primer/probe sets for mouse Ephx3 (Mm01345663_m1) and GADPH 
(Mm99999915_m1) were purchased from Applied Biosystems. Real time RT-
PCR was run with Maxima qPCR Master Mix (Thermo Scientific), analyzed 
using the ABI Prism 7700 thermocycler (Applied Biosystems), and differential 
expression was calculated using the ΔΔ CT method. Primer/probe based 
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expression values were validated by Sybr Green real time RT-PCR (Mouse 
EPHX3 Primers: 5’-tcccatgtcagtgatccaag-3’ and 5’-
tggaagtcagacatagacaacagc-3’).  
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Figure legends 
 
Fig. 1.  Phylogenetic tree of epoxide hydrolases. Boxes represent the linear 
amino acid sequence of human EHs (inside the gray rectangle) compared to 
their C. elegans counterparts. The location of the α/β hydrolase fold domain 
(gray shaded boxes) and the lid domain (black box) is indicated. Dark grey 
boxes represent (potential) N-terminal membrane anchor sequences. 
Sequence alignment was performed using ClustalW (46). The resulting 
dendrogram on the left side indicates the phylogenetic relation. Numbers at 
the bifurcations indicate sequence identity (mean sequence identity ± 
standard deviation, in the case of multiple comparisons). 
 
Fig. 2. Subcellular localization of EH3. Lysates of Sf9 cells expressing human 
EH3 or rat mEH, used as a microsomal marker, were subjected to differential 
centrifugation and subsequent immunoblot analysis. Immunoreactivity for EH3 
and mEH is restricted to the 100,000 x g pellet, indicating their membrane 
association. Abbreviations used are : CL = control insect cell lysate; RL = 
recombinant insect cell lysate; P10 = 10’000 x g pellet; P100 = 100’000 x g 
pellet; S100 = 100’000 x g supernatant. 
 
 
Fig. 3. A. Enzymatic activity analysis of EH3 mutants. Hydrolysis of 9,10- 
epoxystearic acid by the different mutants was assayed using thin layer 
chromatography for the separation of substrate (epoxide) and product (diol) of 
the enzymatic reaction. Identity of the respective mutant is given on top of 
each lane. Of all mutants analyzed, only Y280F and D173N display enzymatic 
activity. B. EH3 active site architecture, deduced from the structural 
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alignments and mutant analyses (for details on the enzymatic mechanism see 
Supporting Information 1). 
 
Fig. 4. Expression pattern of EH3 gene in mouse tissues. mRNA isolated from 
different mouse organs was analyzed by reverse transcriptase-PCR using 
EH3-specific primers. Amplification of GAPDH mRNA served as the control. 
Expression levels in the individual tissues were normalized to those in the 
aortic arch. The bars represent the average obtained from four individual 
isolates, error bars indicate the standard deviation. The insert shows a 
magnification of the results obtained from tissues with lower expression 
yields. 
 
Fig. 5. Kinetic analysis of EH3-catalyzed leukotoxin and EET turnover. Sf9 
cell lysates expressing recombinant EH3 were analyzed for the  hydrolysis of 
leukotoxin, 8,-EET, 11,12-EET and 14,15-EET, using substrate 
concentrations up to 50 µM , dependent on the compound. Larger 
concentrations displayed significant deviations from the Michaelis-Mentewn 
kinetics, presumably due to micelle formation of the substrate. Modelling of 
the Michaelis Menten kinetic (solid line) was performed using Prism 5 
(GraphPad Software, San Diego, CA). 
 
Fig. 6. Determination of IC50 (≈ Ki) of AUDA, CDU and TPAU. EH3 lysate was 
incubated with either of the three strongest inhibitors identified by the 
preliminary screening (see Tab. 2) for 5 min one ice prior to addition of 8,9-
EET (5 µM) and analysis of turnover. The enzymatic activity is expressed in % 
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of activity of the accompanying solvent control (no inhibitor). Kinetics were 
modelled using Prism 5. Note that under the present conditions (substrate 
concentration 7-fold below Km), the IC50 essentially equals Ki (Ki > 90% of 
IC50). 
 
Fig. 7. Comparison of the 11,12-EET turnover kinetics of EH3, sEH and mEH. 
The substrate concentration-dependent reaction velocity for equal amounts of 
each enzyme is displayed. The calculation is based on the experimental data 
given in Tab. 1. While Vmax dictates the reaction velocity at high substrate 
concentrations, in the concentration range far below substrate saturation (see 
inset) the catalytic efficacy is the important predictor. In consequence, the 
ratio of product formed during hydrolysis versus the substrate concentration is 
quite similar for all three enzymes at very low substrate concentrations and 
remains essentially constant with EH3 over the broad range displayed in the 
graph while it rapidly decreases with increasing substrate concentration in the 
case of mEH. The sEH displays an intermediate behaviour. The potential  
implications of these differences are discussed in the text. 
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Table 1. Catalytic properties of EH3 as compared to sEH and mEH 
 
 EH3 sEH mEH 
    
8,9-EET    
Vmax [µmol x mg-1 x min-1] 12 ± 1 0.9 ± 0.1 0.12 ± 0.1 
Km [µM] 30 ± 3 1.7 ± 0.5 0.8 ± 0.25 
kcat/Km [s-1 x M-1] 0.25 x 106 0.5 x 106 0.12 x 106 
    
11,12-EET    
Vmax [µmol x mg-1 x min-1] 50 ± 5 4.5 ± 0.1 0.6 ± 0.03 
Km [µM] 80 ± 10 3.4 ± 0.3 0.4 ± 0.08 
kcat/Km [s-1 x M-1] 0.4 x 106 1.4 x 106 1.2 x 106 
    
14,15-EET    
Vmax [µmol x mg-1 x min-1] 60 ± 5 7 ± 0.3 0.04 ± 0.002 
Km [µM] 130 ± 10 15 ± 4 0.9 ± 0.1 
kcat/Km [s-1 x M-1] 0.3 x 106 0.5 x 106 0.03 x 106 
    
leukotoxin    
Vmax [µmol x mg-1 x min-1] 22 ± 0.5 0.55 ± 0.12 0.008 ± 0.0002 
Km [µM] 25 ± 0.6 1.5 ± 0.5 5.8 ± 0.2 
kcat/Km [s-1 x M-1] 0.6 x 106 0.4 x 106 0.001 x 106 
 
 
Data for Vmax and Km are given as mean ± SD and represent the average of 3 
to 5 independent determinations. kcat/Km is calculated from the means of Vmax 
and Km. 
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Table 2. Inhibition of EH3 catalysis by prototypic EH inhibitors 
 EH3 sEH 
Inhibitor [1 µM] Residual activity  
[% of solvent control ± SD] 
 
1-(1-acetylpiperidin-4-yl)-3- 
(4-(trifluoromethoxy)phenyl)urea (TPAU) 
7.2 ± 1.4** 2.2 ± 0.7** 
12-(3-((3S,5S,7S)-adamantan-1-yl)ureido) 
dodecanoic acid (AUDA) 
5.5 ± 0.1** 1.6 ± 0.5** 
1-cyclohexyl-3-dodecylurea (CDU) 7.5 ± 1.2** 2.0 ± 0.3** 
1-((3S,5S,7S)-adamantan-1-yl)-3- 
(5-(2-(2-ethoxyethoxy)ethoxy)pentyl)urea (AEPU) 
18 ± 0.7** 4.0 ± 1.5** 
8-(3-((3S,5S,7S)-adamantan-1-yl)ureido)octanoic 
acid (AUOA) 
38 ± 3.9** 14 ± 2.6** 
4-(((1R,4R)-4-(3-(4-(trifluoromethoxy)phenyl)ureido) 
cyclohexyl)oxy)benzoic acid (t-TAUCB) 
97 ± 3.3 0.8 ± 0.1** 
4-(((1S,4S)-4-(3-((3S,5S,7S)-adamantan-1-yl) 
ureido)cyclohexyl)oxy)benzoic acid (c-AUCB) 
97 ± 4.6 0.2 ± 0.1** 
4-(((1R,4R)-4-(3-((3S,5S,7S)-adamantan-1-yl) 
ureido)cyclohexyl)oxy)benzoic acid (t-AUCB) 
99 ± 18 1.2 ± 0.2** 
1-((3S,5S,7S)-adamantan-1-yl)-3-cyclohexylurea 
(ACU) 
103 ± 10 8.1 ± 2.2** 
 (E)-octadec-9-enamide (Elaidamide) 75 ± 6.0 130 ± 3.4* 
 
Data are presented as mean ± SD (n=3), compared to vehicle control.  
* = p < 0.05;  ** = p < 0.01 







